The agent storefront at https://agents.pubrio.com/llms.txt?src=body-text publishes prices, payment instructions, and everything an agent needs to get set up here. Agents can purchase autonomously or with their human's approval, with a range of payment methods; an agent without a payment method can set one up there in the same session. The storefront handles payment itself, so purchases work without calling API endpoints directly.
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock on X. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/
Unlock the market timeline & signal feed
3 signals in the last 90 days.
The order this company entered each market — oldest to newest
Director, International Indirect Tax
Director, International Indirect Tax
Sign up to see the full signal feed
How Scholar Rock's international expansion compares to its competitors
Scholar RockYouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Scholar RockYou | 2 | 0 | +100% | 3 | 23 |
Scaling fast — 23 roles opened in the last 90 days, up 56% vs the prior period. Clinical Systems-led and concentrated in United States.
Dublin, County Dublin, Ireland · today
Director, International Indirect Tax
Cambridge, MA · 3d ago
Associate Director, IT Service Delivery & Support
Cambridge, MA · 3d ago
Sr. Director, Infrastructure & Operations
34 technologies detected across the stack.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
2 mentions in the last 90 days.
The obesity drug market is shifting from fat loss to muscle preservation, with new therapies like Scholar Rock's apitegromab gaining FDA approval and showing potential in combination with GLP-1 drugs.
Scholar Rock CEO David Hallal states the company is operating from a position of strength entering a defining period for the SMA community, with BLA submission underway.
Scholar Rock held its Q2 2026 earnings conference call with executives discussing business updates, R&D progress, commercial readiness, and financial results.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Scholar Rock's business, markets, and growth signals.
“We reach accounts the week they land in-market — not the quarter after.”
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
© 2026 Pubrio. All rights reserved.
